Comparative Pharmacology
Head-to-head clinical analysis: HEPSERA versus VITRAVENE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPSERA versus VITRAVENE PRESERVATIVE FREE.
HEPSERA vs VITRAVENE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acyclic nucleotide analog of adenosine monophosphate; inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate dATP, causing DNA chain termination after incorporation into viral DNA.
Antisense oligonucleotide that binds to mRNA of human cytomegalovirus (HCMV), inhibiting viral replication by blocking protein synthesis.
10 mg orally once daily.
Intravitreal injection: 330 mcg (0.05 mL of 6.6 mg/mL solution) every 2 weeks for 2 doses, then every 4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 6-9 hours in patients with normal renal function. In renal impairment, half-life is prolonged (up to 18 hours in moderate impairment, >30 hours in severe impairment). Steady-state is achieved within 5-7 days.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged up to 10 hours.
Primarily renal; 70-90% of an oral dose is excreted unchanged in urine via active tubular secretion and glomerular filtration. Biliary/fecal elimination accounts for <5%.
Primarily renal excretion. Approximately 40% of the dose is excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for less than 5%.
Category C
Category C
Antiviral
Antiviral